Matthew Ferguson - Sep 21, 2023 Form 4 Insider Report for ELUTIA INC. (ELUT)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Jeffrey Hamet, Attorney-in-Fact for Matthew Ferguson
Stock symbol: ELUT
Transactions as of: Sep 21, 2023
Transactions value $: $0
Form type: 4
Date filed: 9/21/2023, 05:50 PM
Previous filing: Mar 9, 2023
Next filing: Feb 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELUT	Class A Common Stock	Award		+70.1K	+138.81%		121K	Sep 21, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELUT	Warrants (rights to buy)	Award		+105K			105K	Sep 21, 2023	Class A Common Stock	105K	$1.43	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are included within the 70,053 Units purchased by the reporting person for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock and one warrant to purchase one and one-half shares of Class A Common Stock.
F2	Includes 901 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.
F3	The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028.